Corona Remedies Limited, a active public limited company, was established on 27 August 2004 in Daskroi, Gujarat, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231GJ2004PLC044656. Registered under ROC Roc Ahmedabad. it is unlisted. It has an authorized capital of ₹61.17 Cr and a paid-up capital of ₹61.16 Cr.
It upholds a compliant status. Employing 4,436 professional, Its leadership includes Ameetkumar Hiranyakumar Desai (Director), Monica Hemal Kanuga (Director), Shirish Gundopant Belapure (Director). Past directors included Ameetkumar Hiranyakumar Desai, Kshitij Pankaj Sheth, Monica Hemal Kanuga. It holds ₹250.00 Cr open charges and ₹112.58 Cr settled loans. Its latest AGM occurred on 26 June 2025, with the balance sheet filed on 31 March 2025. It is based at Corona House, C-Mondeal Business Park, Near Gurudwara, S. G. Highway, Daskroi, Gujarat, 380059.
U24231GJ2004PLC044656
044656
27 August 2004
₹61.17 Cr
₹61.16 Cr
Roc Ahmedabad
Unlisted
Active
Explore comprehensive insights into Corona Remedies Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ameetkumar Hiranyakumar Desai | Director | 22 Nov 2022 | Current |
| Monica Hemal Kanuga | Director | 24 Oct 2024 | Current |
| Shirish Gundopant Belapure | Director | 04 Jan 2025 | Current |
| Nirav Kirtikumar Mehta | Managing Director | 30 May 2007 | Current |
| Ankur Kirtikumar Mehta | Managing Director | 27 Aug 2004 | Current |
| Kirtikumar Laxmidas Mehta | Director | 27 Aug 2004 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 27 Aug 2023 | Past |
| Pramod Abcsdd | Nominee Director | 23 Apr 2025 | Past |
| Pramod Abcsdd | Additional Director | 24 Oct 2024 | Past |
| Pramod Abcsdd | Nominee Director | 31 Dec 2018 | Past |
| Pramod Abcsdd | Director | 01 Jan 2009 | Past |
| Pramod Abcsdd | Director | 11 Apr 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Corona Remedies Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.37% increase. The company also saw a substantial fall in profitability, with a 100.57% decrease in profit. The company's net worth dipped by a decrease of 5.01%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Corona Remedies had a promoter holding of 72.50% and a public holding of 27.50%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,500,000,000.00
₹1,125,836,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Dec 2023 | Others | ₹50.00 Cr | Open |
| 07 Jul 2023 | Citi Bank N.A. | ₹200.00 Cr | Open |
| 28 Aug 2019 | Others | ₹3.28 M | Satisfied |
| 22 Aug 2019 | Others | ₹6.06 M | Satisfied |
| 02 Feb 2019 | Hdfc Bank Limited | ₹50.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Corona Remedies has a workforce of 4436 employees as of Dec 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Corona Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corona Remedies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Corona Remedies Limited last Annual general meeting of members was held on 26 Jun 2025 as per latest MCA records. was recorded as a recent event.
Progress on Chetna Prabhatkumar Dharajiya was appointed as a Company Secretary was appointed as a Company Secretary on 23 Apr 2025 & has been associated with this company since 7 months 6 days . was documented.
The activity Corona Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad. was completed.
The activity Shirish Gundopant Belapure was appointed as a Director was appointed as a Director on 04 Jan 2025 & has been associated with this company since 10 months 23 days . was completed.
Bhaskar Vemban Iyer was appointed as a Director was appointed as a Director on 04 Jan 2025 & has been associated with this company since 10 months 23 days . was recorded as a recent event.
Bhavin Nareshbhai Bhagat was appointed as a Cfo was appointed as a Cfo on 29 Oct 2024 & has been associated with this company since 1 year 29 days . was recorded as a recent event.
CORONA Remedies bought Myoril from Sanofi India for Rs234 crore. Sanofi sold it to focus on chronic diseases. Corona also bought other brands before. Myoril is worth Rs38 crore and growing at 6.8%. Sanofi also sold other brands to different companies. Indian pharma industry is growing at 10% and expected to reach Rs2,95,100 crore by 2026. E-pharmacy and new regulations will help it grow..
The CIN of Corona Remedies Limited is U24231GJ2004PLC044656.
Corona Remedies Limited is headquartered at Corona House, C-Mondeal Business Park, Near Gurudwara, S. G. Highway, Daskroi, Gujarat, 380059.
Corona Remedies Limited was incorporated on 27 August 2004.
The current directors of Corona Remedies Limited are
The primary industry of Corona Remedies Limited is Manufacturing.
Corona Remedies Limited is unlisted.
The authorized capital of Corona Remedies Limited is ₹61.17 Cr, and the paid-up capital is ₹61.16 Cr.
The compliance status of Corona Remedies Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX